<article id="efficacy_CRVO_acuity" class="slide" data-ag-name="Efficacy CRVO Acuity">
  <div class="tab-title">CRVO</div>

  <h2 class="slide-title">RAPID AND SUPERIOR GAINS <br>IN VISUAL ACUITY DEMONSTRATED VS. SHAM<sup class="footnote-link">1</sup><span class="asterisk">*</span></h2>
  <div class="chart">
    <div class="chart-desc">
      Proportion of patients who gained â‰¥15 letters in BCVA from baseline at Week 24 
    </div>
  <div class="chart-img"><img src="content_EN/img/charts_va-crvo.png" /></div>
    <div class="chart-details">
      <span>Adapted from EYLEA<sup class="reg">&reg;</sup> Product Monograph.</span> <span>44.8%, 95% CI (33.0%, 56.6%)</span>
    </div>
    <div class="further-details one-line">
      <p>Rapid improvement observed <b>as early as 4 weeks</b> after the first injection</p>
        <span class="parallelogram"></span>
    </div>
  </div>
    <div class="keys">
      <div class="chart-key">BCVA=best-corrected visual acuity; LOCF=last observation carried forward.</div>
    </div>
  <div class="reveal-study-design"><span>+</span><span>Study Design</span></div>
  <div id="popup-text">
    <h3>STUDY DESIGN</h3>
    <p>
      <span class='bullet'>*</span>A randomized, multicentre, double-masked, sham-controlled study in adult patients with macular edema secondary to CRVO. Patients were assigned randomly in a 3:2 ratio to either EYLEA<sup class="reg">&reg;</sup> 2&nbsp;mg (n=114) or sham (n=74) injections every 4 weeks for the 24 weeks (for a total of 6 injections).
    </p>
  </div>
</article>